Search Result

Results for "

addiction

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Adenosine Deaminase (1) Apoptosis (3) CRFR (1) Dopamine Receptor (8) Dopamine Transporter (2) Drug Metabolite (1) Endogenous Metabolite (1) GABA Receptor (3) Histamine Receptor (1) Integrin (1) Isotope-Labeled Compounds (1) mGluR (6) Monoamine Transporter (3) nAChR (8) Neuropeptide S Receptor (1) Neuropeptide Y Receptor (2) Opioid Receptor (8) Orexin Receptor (OX Receptor) (2) Parasite (1) PKC (2) Pyruvate Kinase (1) RGS Protein (1) Sigma Receptor (1) Sodium Channel (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (54)

By Targets:

5-HT Receptor (4)

Adenosine Deaminase (1)

Apoptosis (3)

CRFR (1)

Dopamine Receptor (8)

Dopamine Transporter (2)

Drug Metabolite (1)

Endogenous Metabolite (1)

GABA Receptor (3)

Histamine Receptor (1)

Integrin (1)

Isotope-Labeled Compounds (1)

mGluR (6)

Monoamine Transporter (3)

nAChR (8)

Neuropeptide S Receptor (1)

Neuropeptide Y Receptor (2)

Opioid Receptor (8)

Orexin Receptor (OX Receptor) (2)

Parasite (1)

PKC (2)

Pyruvate Kinase (1)

RGS Protein (1)

Sigma Receptor (1)

Sodium Channel (1)

By Research Areas:

Cancer (7)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (3)

Metabolic Disease (2)

Neurological Disease (54)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103417

SKF 77434 hydrobromide	Dopamine Receptor	Neurological Disease
SKF 77434 hydrobromide is a selective dopamine D1 receptor partial agonist. SKF 77434 hydrobromide has the potential to study cocaine addiction .

HY-117883

GZ-793A	Monoamine Transporter	Neurological Disease
GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an K_i of 0.029 μM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction .

HY-114237

GDC-0276	Sodium Channel	Neurological Disease
GDC-0276 is a potent, selective, reversible and orally active NaV1.7 inhibitor with an IC₅₀ value of 0.4 nM. GDC-0276 is well tolerated and exhibits a good pharmacokinetic profile. GDC-0276 has the potential for the treatment of pain and to address shortcomings of existing pain medications, such as addiction and off-target side effects .

HY-P3646

[DAla2] Dynorphin A (1-9) (porcine)	Opioid Receptor	Neurological Disease
[DAla2] Dynorphin A (1-9) (porcine) is a dynorphin, which can be used in studies of analgesic, addiction, and depression.

HY-157931

Anticancer agent 192	Histamine Receptor	Neurological Disease
Anticancer agent 192 (compound XXI) is a steroid-based histamine H3 receptor antagonist with no affinity for muscarinics and hERG. Anticancer agent 192 is quite stable in human and rat liver microsomes. Anticancer agent 192 can improve the cognitive level and reduce the degree of addiction in rats in the in vivo addiction test .

HY-120946

VMY-2-95	nAChR	Neurological Disease
VMY-2-95 is an oral active and blood-brain barrier (BBB) penetrant α4β2 nicotinic acetylcholine receptor desensitizer. VMY-2-95 can be used for study of depression or addiction .

HY-111308

RTI-118	Neuropeptide Y Receptor	Neurological Disease
RTI-118 is a novel small-molecule neuropeptide S receptor (NPSR) antagonist. RTI-118 can relieve agent addiction including selectively decrease self-administration .

HY-119768

(±)-BAK2-66	Dopamine Receptor	Neurological Disease
(±)-BAK2-66 is a selectivity dopamine D3 receptor antagonist with theK_i values of 1nM and 960 nM for D3R and D2R, respectively. (±)-BAK2-66 can be used for study in animal models of addiction .

HY-P3625

Dynorphin (2-17), amide (porcine)	Endogenous Metabolite Opioid Receptor	Neurological Disease
Dynorphin (2-17), amide (porcine) is a dynorphin derivative with some analgesic effects. Dynorphin is a class of opioid peptides produced by the precursor protein dynorphinogen and is involved in pain, addiction and mood regulation .

HY-P2046

β-Endorphin (rat)	Opioid Receptor	Neurological Disease
β-Endorphin (rat) is an endogenous opioid neuropeptide and peptide hormone. β-Endorphin (rat) has analgesic activity and also contributes to food intake in satiated rats. β-Endorphin (rat) can be used in the research of neurological diseases such as analgesia and drug addiction .

HY-P1437

Neuropeptide S (mouse)	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide S (mouse) is a bioactive peptide. Neuropeptide S (mouse), as a neurotransmitter/neuromodulator of 20 amino acids, can be used for the research of arousal, anxiety, locomotion, feeding behaviors, memory and agent addiction .

HY-120527

VU0463841	mGluR	Neurological Disease
VU0463841 is a potent, selective and brain-penetrant mGlu5 negative allosteric modulator (NAM) with an IC₅₀ of 13 nM. VU0463841 is ineffective against mGlu1-4 and mGlu7-8. VU0463841 has the potential for the Cocaine addiction research .

HY-103475

GS39783	GABA Receptor	Neurological Disease
GS39783 is a positive allosteric modulator (PAM) of GABA_BR. Positive modulation of the GABA_BR can be used for the research of Nicotine addiction .

HY-116910

CPP-115	GABA Receptor	Neurological Disease
CPP-115 is a GABA transaminase inactivator with higher affinity and lower retinal toxicity than Vigabatrin (HY-15399). CPP-115 increases brain GABA levels by inhibiting GABA transaminase catabolism. CPP-115 can be used in the study of drug addiction and infantile spasms .

HY-101478

Fenobam	mGluR Apoptosis	Neurological Disease Cancer
Fenobam is a selective and orally active mGluR5 antagonist (IC₅₀=84 nM) that can penetrate the blood-brain barrier. Fenobam shows the K_d values of 54 nM and 31 nM on rat and human recombinant mGlu5 receptors, respectively. Fenobam has anxiolytic activity, inhibits self-administration behavior in mice, and induces apoptosis in cancer cells. Fenobam can be used for research on neurological diseases, cancer and drug addiction .

HY-116820

OS-3-106	Dopamine Receptor	Neurological Disease
OS-3-106 is a potent, BBB-penetrated and selective dopamine D3 receptor (D3R) agonist. OS-3-106 binds with high affinity (K_i = 0.2 nM) at the D3R. OS-3-106 can be used for psychoactivator addiction research .

HY-101478A

Fenobam hydrate	mGluR Apoptosis	Neurological Disease Cancer
Fenobam hydrate is a selective and orally active mGluR5 antagonist (IC₅₀=84 nM) that can penetrate the blood-brain barrier. Fenobam hydrate shows the K_d values of 54 nM and 31 nM on rat and human recombinant mGlu5 receptors, respectively. Fenobam hydrate has anxiolytic activity, inhibits self-administration behavior in rat, and induces apoptosis in cancer cells. Fenobam hydrate can be used for research on neurological diseases, cancer and drug addiction .

HY-101834

ACT-462206	Orexin Receptor (OX Receptor)	Others
ACT-462206 is an orally active and potent dual Orexin 1/Orexin 2 receptor antagonist with IC₅₀s of 60 nM (Orexin 1) and 11 nM (Orexin 2), respectively. ACT-462206 exhibits brain penetration properties, and can be used for insomnia, stress/anxiety-related disorders and addiction research .

HY-153458

Orexin receptor modulator-1	Orexin Receptor (OX Receptor)	Cardiovascular Disease Neurological Disease Metabolic Disease
Orexin receptor modulator-1 is an orexin receptor modulator. Orexin receptor modulator-1 can be used for the research of substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension .

HY-103673

AMPD2 inhibitor 1	Adenosine Deaminase	Neurological Disease
AMPD2 inhibitor 1 is an adenosine monophosphate deaminase 2 (AMPD2) inhibitor, used in the research of sugar craving, salt craving, umami craving, and addictions including agent, tobacco, nicotine and alcohol addictions.

HY-147319

RTI-7470-44	Others	Neurological Disease
RTI-7470-44 is a potent, selective and blood-brain barrier (BBB) penetrant human trace amine-associated receptor subtype 1 (hTAAR1) antagonist with an IC₅₀ value of 8.4 nM and a K_i value of 0.3 nM. RTI-7470-44 has moderate metabolic stability, and a favorable preliminary off-target profile. RTI-7470-44 can increase the spontaneous firing rate of mouse ventral tegmental area (VTA) dopaminergic neurons. RTI-7470-44 can be used for researching schizophrenia, agent addiction, and Parkinson’s disease (PD) .

HY-13052

SB-737050A	5-HT Receptor	Neurological Disease
SB-737050A is a potent 5-HT6 antagonist to prevent relapse into addiction .

HY-124110

TC299423	nAChR	Neurological Disease
TC299423 is an orally active, brain-penetrant, selective and potent agonist for α6β2 ^∗ and α4β2 ^∗ nicotinic acetylcholine receptors (nAChRs) with anxiolytic and antinociceptive properties. TC299423 acts primarily through α6β2 ^∗ nAChRs that are implicated in the anxiolytic effects of nicotine. TC299423 elicits reward-related behavior mediated through α6β2 ^∗ nAChRs in hypersensitive α6L90’S mice. TC299423 elicits dopamine release and dose not suppress nicotine self-administration in rats. TC299423 is proming for rasearch of addiction and Parkinson’s disease .

HY-17030

Acamprosate calcium Calcium N-acetylhomotaurinate	GABA Receptor	Neurological Disease
Acamprosate calcium(Campral EC) is a GABA receptor agonist and modulator of glutamatergic systems; reduces alcohol consumption in animal models of alcohol addiction.

HY-W703869

5-Hydroxy NMT oxalate N-Methylserotonin oxalate; 5-Hydroxy-N-methyl tryptamine oxalate	Drug Metabolite	Neurological Disease
5-Hydroxy NMT (N-Methylserotonin) oxalate is a metabolite of 5-HT and belongs to the tryptamine class of compounds. Elevated levels of 5-Hydroxy NMT oxalate in plasma are associated with cocaine addiction .

HY-116181

YQA14	Dopamine Receptor	Neurological Disease
YQA14 is a high affinity dopamine D3 receptor antagonist. YQA14 is anti-opioid addiction agent. YQA14 inhibits Morphine/Cocaine-induced conditioned place preference (CPP) in animals .

HY-122133

CI 750	Others	Metabolic Disease
CI 750 is a potent and orally active antidiarrheal agent. CI 750 increases the motor pattern of the gastrointestinal tract. CI 750 shows a constipating activity. CI 750 shows no analgesic, addiction liability, or anticholinergic pharmacological activity .

HY-12698

NNC 63-0532	Opioid Receptor	Neurological Disease
NNC63-0532 is a novel non-peptide nociceptin receptor (ORL1) agonist, with EC₅₀s of 305?nM. NNC63-0532 plays important roles in many disorders such as pain, drug addiction .

HY-N6960

L-Stepholidine Stepholidine; (-)-Stepholidine; L-SPD	Dopamine Receptor	Neurological Disease
L-Stepholidine (Stepholidine) exhibits mixed dopamine D1 receptor agonist and D2 antagonist properties. L-Stepholidine has neuroprotective effect and inhibits Heroin-induced reinstatement. L-Stepholidine is a potential medication for the research of opiate addiction .

HY-107457

AZD-8529 1 Publications Verification	mGluR	Neurological Disease
AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2, with an EC₅₀ of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes.

HY-12697

NGB 2904	Dopamine Receptor	Neurological Disease
NGB 2904 is a potent, selective, orally active and brain-penetrated antagonist of dopamine D3 receptor, with a K_i of 1.4 nM. NGB 2904 shows selectivity for D3 over D2, 5-HT2, α1, D4, D1 and D5 receptors (K_is=217, 223, 642, >5000, >10000 and >10000 nM, respectively). NGB 2904 antagonizes Quinpirole-stimulated mitogenesis .

HY-108626

ML154 NCGC84	Neuropeptide S Receptor	Neurological Disease
ML154 (NCGC84) is a selective, brain-penetrant and non-peptide neuropeptide S receptor (NPSR) antagonist with a pA₂ of 9.98. ML154 potently inhibits NPS-stimulated cellular calcium, cAMP, and ERK phosphorylation responses with IC₅₀ values of 36.5 nM, 22.1 nM, and 9.3 nM, respectively .

HY-103573

VU 0360223	mGluR	Neurological Disease
VU 0360223 is a potent metabotropic glutamate receptors (mGluR) negative allosteric modulator with an IC₅₀ of 61 nM .

HY-107457A

AZD-8529 mesylate 1 Publications Verification	mGluR	Neurological Disease
AZD-8529 mesylate is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2, with an EC₅₀ of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes .

HY-P2298

TAT-P4-(DATC5)2	PKC	Neurological Disease
TAT-P4-(DATC5)2 is a high-affinity peptide inhibitor of the PICK1 (protein interacting with C kinase-1) PDZ domain, with a K_i of 1.7 nM. TAT-P4-(DATC5)2 can inhibit addiction in rats .

HY-P2298A

TAT-P4-(DATC5)2 TFA	PKC	Neurological Disease
TAT-P4-(DATC5)2 TFA is a high-affinity peptide inhibitor of the PICK1 (protein interacting with C kinase-1) PDZ domain, with a K_i of 1.7 nM. TAT-P4-(DATC5)2 TFA can inhibit addiction in rats .

HY-122251

CCG-4986	RGS Protein	Others Neurological Disease
CCG-4986 is an RGS protein inhibitor. CCG-4986 inhibits protein activity by covalently modifying the Cys-132 site of RGS4. CCG-4986 can be used to study diseases related to dysregulated G protein-coupled receptor (GPCR) signaling, such as Parkinson's disease and opioid addiction .

HY-P1335

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-114085

BP 897	Dopamine Receptor	Neurological Disease
BP 897 is a potent and partial dopamine D3 receptor agonist and a weak D2 receptor antagonist. BP 897 displays a high affinity at the dopamine D3 receptor (K_i=0.92 nM) and a 70 times lower affinity at the D2 receptor (K_i=61 nM) .

HY-106660

BP 897 hydrochloride	Dopamine Receptor	Neurological Disease
BP 897 hydrochloride is a potent and partial dopamine D3 receptor agonist and a weak D2 receptor antagonist. BP 897 hydrochloride displays a high affinity at the dopamine D3 receptor (K_i=0.92 nM) and a 70 times lower affinity at the D2 receptor (K_i=61 nM) .

HY-155850

CIAC001	Pyruvate Kinase	Neurological Disease
CIAC001 is a Pyruvate Kinase PKM2 inhibitor with anti-neuroinflammatory activity. CIAC001 inhibits LPS-induced proinflammatory nitric oxide (NO) production and protects immunologically active BV-2 cells (IC₅₀=2.5 μM). CIAC001 also has anti-neuroinflammation in mouse models and inhibits chronic morphine-induced addiction .

HY-P1335A

CTAP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-137231B

(S)-UFR2709 hydrochloride	nAChR	Neurological Disease
(S)-UFR2709 (hydrochloride) is a competitive nAChR antagonist?and displays higher affinity for α₄β₂ nAChRs than for α₇ nAChRs. (S)-UFR2709 (hydrochloride) decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 (hydrochloride) acts as an anxiolytic agent and can be used for the study of nicotine addiction .

HY-137231A

(S)-UFR2709	nAChR	Neurological Disease
(S)-UFR2709 is a competitive nAChR antagonist and displays higher affinity for α₄β₂ nAChRs than for α₇ nAChRs. (S)-UFR2709 decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 acts as an anxiolytic agent and can be used for the study of nicotine addiction .

HY-12844

Ro 64-6198 1 Publications Verification	Opioid Receptor	Neurological Disease
Ro 64-6198 is a potent, selective, nonpeptide, high-affinity, high cellular permeability and brain penetration N/OFQ receptor (NOP) agonist with an EC₅₀ value of 25.6 nM. Ro 64-6198 is at least 100 times more selective for the NOP receptor over the classic opioid receptors. Ro 64-6198 can be used for stress and anxiety, addiction, neuropathic pain, cough, and anorexia .

HY-P1625

Daeatal Dynorphin A ethylamide (1-9)	Opioid Receptor	Neurological Disease
Daeatal (Dynorphin A ethylamide (1-9)) is an ethylamine-modified dynorphin fragment that can be used in the study of analgesia, addiction, depression, etc. Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .

HY-147428

Zolunicant MM-110; (±)-18-Methoxycoronaridine	nAChR Parasite	Infection Neurological Disease
Zolunicant (MM-110) is a potent inhibitor against nicotinic α3β4 receptors with an IC₅₀ of 0.90 μM to combat addiction. Zolunicant can decrease the self-administration of several addictive agents including morphine, methamphetamine, nicotine, and ethanol in rat model. Zolunicant can be studied as a potential research for multiple forms of agent abuse . Zolunicant also reveals a potent leishmanicide effect against Leishmania amazonensis .

HY-157172

MorHap	Integrin	Infection Neurological Disease
MorHap is a heroin hapten. MorHap conjugated to tetanus toxoid (TT), palm-CV2, and to monophosphoryl lipid A (MPLA)-containing liposomes partially blocks heroin-induced analgesia and hyperlocomotion in mice. MorHap designed conjugates also significantly inhibits HIV-1 binding to α4β7 receptors. MorHap can be used in research to develop vaccines related to heroin addiction and HIV-1 infection .

HY-120788

VMAT2-IN-4	Monoamine Transporter	Others
VMAT2-IN-4 (compound 11) is a vesicular monoamine transporter-2 (VMAT2) inhibitor. VMAT2-IN-4 inhibits [ ³H]-DTBZ binding (Ki = 560 nM). VMAT2-IN-4 inhibits [ ³H]-DA (Ki = 45 nM) from entering vesicles and being taken up by cells. VMAT2-IN-4 can be used in methamphetamine addiction research .

HY-10019AS1

Varenicline-d4 hydrochloride	Isotope-Labeled Compounds nAChR	Inflammation/Immunology
Varenicline-d₄ hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A) . Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment .

Cat. No.	Product Name

HY-L083

Anti-Cancer Metabolism Compound Library

2,524 compounds

Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth.

MCE provides a unique collection of 2,524 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P1437

Neuropeptide S (mouse)	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide S (mouse) is a bioactive peptide. Neuropeptide S (mouse), as a neurotransmitter/neuromodulator of 20 amino acids, can be used for the research of arousal, anxiety, locomotion, feeding behaviors, memory and agent addiction .

HY-P1335A

CTAP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P3646

[DAla2] Dynorphin A (1-9) (porcine)	Opioid Receptor	Neurological Disease
[DAla2] Dynorphin A (1-9) (porcine) is a dynorphin, which can be used in studies of analgesic, addiction, and depression.

HY-P3625

Dynorphin (2-17), amide (porcine)	Endogenous Metabolite Opioid Receptor	Neurological Disease
Dynorphin (2-17), amide (porcine) is a dynorphin derivative with some analgesic effects. Dynorphin is a class of opioid peptides produced by the precursor protein dynorphinogen and is involved in pain, addiction and mood regulation .

HY-P2046

β-Endorphin (rat)	Opioid Receptor	Neurological Disease
β-Endorphin (rat) is an endogenous opioid neuropeptide and peptide hormone. β-Endorphin (rat) has analgesic activity and also contributes to food intake in satiated rats. β-Endorphin (rat) can be used in the research of neurological diseases such as analgesia and drug addiction .

HY-P2298

TAT-P4-(DATC5)2	PKC	Neurological Disease
TAT-P4-(DATC5)2 is a high-affinity peptide inhibitor of the PICK1 (protein interacting with C kinase-1) PDZ domain, with a K_i of 1.7 nM. TAT-P4-(DATC5)2 can inhibit addiction in rats .

HY-P2298A

TAT-P4-(DATC5)2 TFA	PKC	Neurological Disease
TAT-P4-(DATC5)2 TFA is a high-affinity peptide inhibitor of the PICK1 (protein interacting with C kinase-1) PDZ domain, with a K_i of 1.7 nM. TAT-P4-(DATC5)2 TFA can inhibit addiction in rats .

HY-P1335

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P1625

Daeatal Dynorphin A ethylamide (1-9)	Opioid Receptor	Neurological Disease
Daeatal (Dynorphin A ethylamide (1-9)) is an ethylamine-modified dynorphin fragment that can be used in the study of analgesia, addiction, depression, etc. Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6960

L-Stepholidine Stepholidine; (-)-Stepholidine; L-SPD	Alkaloids Stephania intermedia Source classification Plants Isoquinoline Alkaloids Menispermaceae	Dopamine Receptor
L-Stepholidine (Stepholidine) exhibits mixed dopamine D1 receptor agonist and D2 antagonist properties. L-Stepholidine has neuroprotective effect and inhibits Heroin-induced reinstatement. L-Stepholidine is a potential medication for the research of opiate addiction .

HY-N7506

13-Hydroxyisobakuchiol Delta3,2-Hydroxylbakuchiol	Structural Classification Monophenols Leguminosae Source classification Phenols Psoralea corylifolia L. Plants	Monoamine Transporter Dopamine Transporter
Hydroxyisobakuchiol (Delta3,2-Hydroxylbakuchiol), an analog of Bakuchiol (HY-N0235) isolated from Psoralea corylifolia (L.), is a potent monoamine transporter inhibitor. 13-Hydroxyisobakuchiol is more selective for the dopamine transporter (DAT) (IC₅₀=0.58 μM) and norepinephrine transporter (NET) (IC₅₀=0.69 μM) than for the serotonin transporter (SERT) (IC₅₀=312.02 μM). 13-Hydroxyisobakuchiol has the potential for the research of disorders such as Parkinson's disease and depression .

Cat. No.	Product Name	Chemical Structure

HY-10019AS1

Varenicline-d4 hydrochloride

Varenicline-d₄ hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A) . Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

addiction

Inhibitors & Agonists

Screening Libraries

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products